

Hanping Wang

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8875692/hanping-wang-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51
papers

629
citations

12
h-index

23
g-index

65
ext. papers

851
ext. citations

3.2
avg, IF

5.44
L-index

#	Paper	IF	Citations
51	Risk of COVID-19 for patients with cancer. <i>Lancet Oncology, The</i> , 2020 , 21, e181	21.7	286
50	Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018 , 122, 32-37	5.9	27
49	Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. <i>Thoracic Cancer</i> , 2020 , 11, 191-197	3.2	26
48	Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. <i>Thoracic Cancer</i> , 2019 , 10, 551-556	3.2	25
47	Diffuse Cystic Lung Diseases: Diagnostic Considerations. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016 , 37, 457-67	3.9	19
46	Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients. <i>Thoracic Cancer</i> , 2020 , 11, 1621-1632	3.2	18
45	Biopsy-proven IgG4-related lung disease. <i>BMC Pulmonary Medicine</i> , 2016 , 16, 20	3.5	17
44	Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy. <i>Lung Cancer</i> , 2018 , 125, 142-149	5.9	16
43	Clinical and diagnostic features of angiosarcoma with pulmonary metastases: A retrospective observational study. <i>Medicine (United States)</i> , 2017 , 96, e8033	1.8	15
42	Development of an UPLC-MS/MS method for quantification of Avitinib (AC0010) and its five metabolites in human cerebrospinal fluid: Application to a study of the blood-brain barrier penetration rate of non-small cell lung cancer patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017 , 139, 205-214	3.5	13
41	Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events. <i>Thoracic Cancer</i> , 2020 , 11, 799-804	3.2	13
40	Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation. <i>Lung Cancer</i> , 2018 , 122, 1-6	5.9	13
39	Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. <i>Thoracic Cancer</i> , 2020 , 11, 810-818	3.2	11
38	Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib. <i>Thoracic Cancer</i> , 2020 , 11, 594-602	3.2	9
37	Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2020 , 11, 1647-1654	3.2	9
36	Management of immune checkpoint inhibitor-related adverse events: A review of case reports. <i>Thoracic Cancer</i> , 2020 , 11, 498-504	3.2	6
35	Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor-induced renal immune-related adverse events. <i>Thoracic Cancer</i> , 2020 , 11, 1746-1751	3.2	6

34	Management of immune checkpoint inhibitor-related dermatologic adverse events. <i>Thoracic Cancer</i> , 2020 , 11, 488-492	3.2	6
33	Use of glucocorticoids in the management of immunotherapy-related adverse effects. <i>Thoracic Cancer</i> , 2020 , 11, 3047-3052	3.2	6
32	Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study. <i>Cancer Medicine</i> , 2021 , 10, 188-198	4.8	6
31	Tocilizumab for Fulminant Programmed Death 1 Inhibitor-Associated Myocarditis. <i>Journal of Thoracic Oncology</i> , 2020 , 15, e31-e32	8.9	5
30	Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma. <i>Thoracic Cancer</i> , 2018 , 9, 1056-1061	3.2	5
29	The ability of avitinib to penetrate the blood brain barrier and its control of intra-/extra- cranial disease in patients of non-small cell lung cancer (NSCLC) harboring EGFR T790M mutation.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20613-e20613	2.2	5
28	Genomic characteristics of driver genes in Chinese patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021 , 12, 357-363	3.2	5
27	Single-center study to determine the safety and efficacy of CT-707 in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small-cell lung cancer. <i>Thoracic Cancer</i> , 2020 , 11, 1216-1223	3.2	4
26	Histologic transformation of lung cancer during pembrolizumab therapy: A case report. <i>Thoracic Cancer</i> , 2020 , 11, 793-796	3.2	4
25	Evaluation of Lung Cancer and Neuroendocrine Neoplasm in a Single Scan by Targeting Both Somatostatin Receptor and Integrin $\alpha\beta$. <i>Clinical Nuclear Medicine</i> , 2019 , 44, 687-694	1.7	4
24	Opportunistic infections complicating immunotherapy for non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020 , 11, 1689-1694	3.2	4
23	Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy. <i>OncoTargets and Therapy</i> , 2018 , 11, 7513-7519	4.4	4
22	Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy. <i>BMC Medicine</i> , 2021 , 19, 154	11.4	4
21	Acute exacerbation of asthma induced by combined therapy of programmed death-1 Blocker plus lenvatinib in a patient with advanced hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2021 , 156, 122-124	7.5	4
20	Clinical diagnosis and treatment of immune checkpoint inhibitor-associated adverse events in the digestive system. <i>Thoracic Cancer</i> , 2020 , 11, 829-834	3.2	3
19	Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections. <i>Thoracic Cancer</i> , 2020 , 11, 805-809	3.2	3
18	A validated ultra-HPLC-MS/MS method for determination of honokiol in human plasma and its application to a clinical pharmacokinetic study. <i>Bioanalysis</i> , 2019 , 11, 1085-1098	2.1	3
17	Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease. <i>OncoTargets and Therapy</i> , 2019 , 12, 5545-5549	4.4	3

16	Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity. <i>Thoracic Cancer</i> , 2020 , 11, 475-480	3.2	3
15	NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score. <i>Cancer Management and Research</i> , 2020 , 12, 5975-5985	3.6	3
14	A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920965849	5.4	2
13	Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum-pemetrexed: The first report of two cases. <i>Thoracic Cancer</i> , 2020 , 11, 2339-2342	3.2	2
12	Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction. <i>Thoracic Cancer</i> , 2020 , 11, 1099-1104	3.2	2
11	Tracheoesophageal Fistula Caused by Successful Response to Pembrolizumab in a Patient With Squamous Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019 , 14, e141-e143	8.9	1
10	A Bayesian network meta-analysis regarding the comparative efficacy of therapeutics for ALK-positive, brain metastatic non-small cell lung cancer. <i>Pharmacological Research</i> , 2021 , 174, 105931	10.2	1
9	Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma. <i>Frontiers in Oncology</i> , 2021 , 11, 728253	5.3	1
8	Management of immune checkpoint inhibitor-related rheumatic adverse events. <i>Thoracic Cancer</i> , 2020 , 11, 198-202	3.2	1
7	Lack of a pulmonary vein causing unilateral interlobular septal thickening. <i>Thorax</i> , 2018 , 73, 199-200	7.3	1
6	Fasciitis induced by sintilimab in a patient with recurrent hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2021 , 155, 296-298	7.5	1
5	Leptomeningeal enhancement in magnetic resonance imaging predicts poor prognosis in lung adenocarcinoma patients with leptomeningeal metastasis.. <i>Thoracic Cancer</i> , 2022 ,	3.2	1
4	Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor-associated adverse events. <i>Thoracic Cancer</i> , 2020 , 11, 2077-2086	3.2	0
3	The role of epidermal growth factor receptor mutations (EGFRm) in NSCLC with leptomeningeal metastasis: A prospective observational study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e19070-e19070	2.2	
2	Phase Ib study of safety, tolerability and pharmacokinetics of simotinib in patients with advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20642-e20642	2.2	
1	Conversion therapy of stage IVb unresectable gallbladder carcinoma.. <i>Hepatobiliary Surgery and Nutrition</i> , 2022 , 11, 335-337	2.1	